Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
- PMID: 12232749
- PMCID: PMC2364257
- DOI: 10.1038/sj.bjc.6600543
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
Abstract
We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29-84%) and the median overall survival time was 9.5 months (range 0.9-26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.
References
-
- AndréTLouvetCRaymondETournigandCde GramontA1998Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 912511253 - PubMed
-
- GebbiaVGiulianiFMaielloEColucciGVerderameFBorsellinoNMauceriGCarusoMTirritoMLValdesiM2001Treatment of inoperable and/or metastatic biliary tree carcinomas with single agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study J Clin Oncol 1940894090 - PubMed
-
- GlimeliusBHoffmanKSjödenPOJacobssonGSellströmHEhanderLKLinnéTSvenssonC1996Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7593600 - PubMed
-
- HejnaMPruckmayerMRadererM1998The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature Eur J Cancer 34977986 - PubMed
-
- KaplanELMaierP1959Non-Parametric estimation from incomplete oberservations J Am Stat Assoc 53457481
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources